Aspen Pharmacare | APN

Aspen Pharmacare traded at 17,734.00 this Monday March 20th, decreasing 0 or 0 percent since the previous trading session. Looking back, over the last four weeks, Aspen Pharmacare lost 18.56 percent. Over the last 12 months, its price fell by 8.86 percent. Looking ahead, we forecast Aspen Pharmacare to be priced at 17,145.23 by the end of this quarter and at 15,493.63 in one year, according to Trading Economics global macro models projections and analysts expectations.


Ok
Trading Economics members can view, download and compare data from nearly 200 countries, including more than 20 million economic indicators, exchange rates, government bond yields, stock indexes and commodity prices.

The Trading Economics Application Programming Interface (API) provides direct access to our data. It allows API clients to download millions of rows of historical data, to query our real-time economic calendar, subscribe to updates and receive quotes for currencies, commodities, stocks and bonds.

API Features Documentation Interested? Click here to contact us
Please Paste this Code in your Website
width
height
 Preview
Peers Price Day Year
Jiangsu Hengrui Me. 41.35 0.95 2.35% 11.94%
Adcock Ingram Holdings Ltd 5,174.00 74.00 1.45% -1.22%
Aspen Pharmacare 17,734.00 0 0% -8.86%
Cipla 870.20 3.50 0.40% -17.15%
Dr.Reddys Laboratories 4,463.35 23.90 0.54% 11.45%
Kalbe Farma 2,140.00 -30.00 -1.38% 29.31%
Life Healthcare 1,873.00 -1.00 -0.05% -16.94%
Netcare 1,428.00 9.00 0.63% -3.77%
Richter Gedeon 7,450.00 150.00 2.05% 3.47%

Indexes Price Day Year
SA40 68799 1,798.12 2.68% -0.50%
SAALL 74271 1,743.14 2.40% -1.95%

Aspen Pharmacare
Aspen Pharmacare Holdings Limited is a South Africa-based global specialty and branded pharmaceutical company with a commercial footprint covering more than 50 countries and complex manufacturing capabilities in both active pharmaceutical ingredients (APIs) and finished dose form. The Company is focused on marketing and manufacturing a broad range of post-patent, branded medicines and domestic brands covering both hospital and consumer markets through its key business segments: Manufacturing and Commercial Pharmaceuticals. The Manufacturing segment relates to the manufacture and sale of APIs and finished dose form products to third-party customers. Its Commercial Pharmaceuticals segment comprises Regional Brands and Sterile Focus Brands that include Anaesthetics and Thrombosis products. It operates approximately 23 manufacturing facilities on six continents. Its manufacturing capabilities cover a wide variety of product-types, including orals, liquids, steriles, biologicals and APIs.